Trials / Completed
CompletedNCT01847092
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Ardelyx · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1722 | |
| DRUG | Placebo | Placebo for AZD1722 |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-03-01
- Completion
- 2015-04-01
- First posted
- 2013-05-06
- Last updated
- 2020-05-27
- Results posted
- 2020-05-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01847092. Inclusion in this directory is not an endorsement.